Positive results for Jardiance in Type 2 Diabetes-Boehringer/Eli Lilly

Jardiance (empagliflozin), from Boehringer and Eli Lilly, reduced hemoglobin A1C (a measure of average blood sugar over the past two to three months), body weight and several markers of abdominal fat in adults with Type 2 Diabetes (T2D), according to a new retrospective analysis presented at the 2014 Scientific Sessions of the American Heart Association. Treatment with empagliflozin significantly reduced A1C, body weight and several markers of abdominal fat compared with placebo. Changes in estimated total body fat did not reach statistical significance.

In the 12-week study, A1C was significantly reduced from a baseline of 7.90 percent by 0.64 percent with empagliflozin. Body weight was significantly reduced, from a baseline of 95 kg, by 1.7 kg with empagliflozin. In the pooled analysis of four 24-week studies, A1C was significantly reduced from a baseline of 7.97 percent by 0.65 percent with empagliflozin. Body weight was significantly reduced, from a baseline of 79 kg, by 1.9 kg.